BIOMAT Database Logo BIOMAT Database Logo

Neocarzinostatin: report of a phase II clinical trial. 1981

E M McKelvey, and W Murphy, and A Zander, and G P Bodey

Fifty-three patients received intensive treatment with neocarzinostatin in doses of 3500 units/m2 by iv bolus infusion daily for 5-14 days. The response rate for 22 patients with leukemia was 9%. One complete and one partial remission were observed among nine patients with chronic myelogenous leukemia in blast cell crisis. None of the 31 patients with solid tumors responded to treatment. With this dose schedule, prolonged thrombocytopenia and cumulative bone marrow toxicity limit the intensity and duration of neocarzinostatin therapy. Acute allergic reactions occurred in 28% of the treatment courses, and three patients developed anaphylaxis during the second or third course of therapy.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D009353 Zinostatin An enediyne that alkylates DNA and RNA like MITOMYCIN does, so it is cytotoxic. Neocarzinostatin
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001855 Bone Marrow Diseases Diseases involving the BONE MARROW. Bone Marrow Disease,Disease, Bone Marrow,Diseases, Bone Marrow,Marrow Disease, Bone,Marrow Diseases, Bone
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E M McKelvey, and W Murphy, and A Zander, and G P Bodey
Phase I and preliminary phase II study of neocarzinostatin.
December 1978, Cancer treatment reports,
E M McKelvey, and W Murphy, and A Zander, and G P Bodey
[A phase II clinical trial of pepleomycin].
September 1996, Zhonghua zhong liu za zhi [Chinese journal of oncology],
E M McKelvey, and W Murphy, and A Zander, and G P Bodey
[Phase II clinical trial of MCNU].
July 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
E M McKelvey, and W Murphy, and A Zander, and G P Bodey
Early termination of a phase II clinical trial.
September 1988, Controlled clinical trials,
E M McKelvey, and W Murphy, and A Zander, and G P Bodey
[Phase II clinical trial on mitoxantrone].
May 1989, Zhonghua zhong liu za zhi [Chinese journal of oncology],
E M McKelvey, and W Murphy, and A Zander, and G P Bodey
Interpreting a Bayesian phase II futility clinical trial.
November 2022, Trials,
E M McKelvey, and W Murphy, and A Zander, and G P Bodey
[Phase II clinical trial of anticancer drugs].
July 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
E M McKelvey, and W Murphy, and A Zander, and G P Bodey
Benefit of early Class II treatment: progress report of a two-phase randomized clinical trial.
January 1998, American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics,
E M McKelvey, and W Murphy, and A Zander, and G P Bodey
Phase II trial of neocarzinostatin in patients with bladder and prostatic cancer: toxicity of a five-day iv bolus schedule.
June 1980, Cancer,
E M McKelvey, and W Murphy, and A Zander, and G P Bodey
Bortezomib therapy in myelofibrosis: a phase II clinical trial.
August 2008, Leukemia,
Copied contents to your clipboard!